Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review

DBV Technologies has submitted a Biologics License Application (BLA) to the U.S. FDA for the VIASKIN Peanut Patch aimed at children aged 4-7 with peanut allergies. This application is backed by results from the Phase 3 VITESSE trial, which is noted as the largest immunotherapy clinical trial for this demographic. The company has also requested Priority Review for the BLA.